Answers are grounded in this paper and cite their sources.
An infusion of prostacyclin (PGI2) in four patients with pulmonary hypertension resulted in a dose-related decrease in the systemic and pulmonary vascular resistance and an increase in cardiac output. No selectivity for the pulmonary vasculature was observed and the drug was not therapeutically beneficial.
No takes yet. Share an insight, caveat, or question.
Guadagni et al. (1981) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: